Combination of Posaconazole and Amphotericin B in the Treatment of <i>Candida glabrata</i> Biofilms

Candidemia cases have been increasing, especially among immunosuppressed patients. <i>Candida glabrata</i> is one of the most resistant <i>Candida</i> species, especially to the azole drugs, resulting in a high demand for therapeutic alternatives. The minimum inhibitory conce...

Full description

Bibliographic Details
Main Authors: Célia F. Rodrigues, Diana F. Alves, Mariana Henriques
Format: Article
Language:English
Published: MDPI AG 2018-12-01
Series:Microorganisms
Subjects:
Online Access:https://www.mdpi.com/2076-2607/6/4/123
Description
Summary:Candidemia cases have been increasing, especially among immunosuppressed patients. <i>Candida glabrata</i> is one of the most resistant <i>Candida</i> species, especially to the azole drugs, resulting in a high demand for therapeutic alternatives. The minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC), and minimum biofilm eradication concentration (MBEC) were determined for posaconazole (Pcz) and amphotericin B (AmB). The drug combinations of both drugs were evaluated on pre-formed biofilms of <i>C. glabrata</i> ATCC 2001, through XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay, colony forming units (CFU), crystal violet, and the fractional inhibitory concentration index (FICI). <i>C. glabrata</i> revealed higher susceptibility and biofilm reduction in the presence of AmB alone, but both drugs revealed a good capacity in the biomass elimination. In the majority of the tested combinations, the interactions were defined as indifferent (FICI &#8804; 4). The combination of the two drugs does not seem to bring a clear advantage in the treatment of biofilms of <i>C. glabrata</i>.
ISSN:2076-2607